In women of HER2-negative cancers, the 5-year breast cancer-specific survival rates were 84 % (95 % confidence interval = 67 to 92 %) for women of positive stomatin expression and 94 % for women of negative stomatin expression (95 % confidence interval = 67 to 99 %, p = 0.193). Here, ERBB2 is linked to cancer.